Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus Abstract #1642

Introduction: More than 10% of patient treated with Everolimus develop early onset of resistance. The lacking of adequate predictive factors in the targeted hera makes challenging the early identification of non-responders patients.
Aim(s): This is a biological prospective trial (clinicaltrials.gov:NCT02305810) in 38 patients treated with RAD001 which aims to find soluble predictive factors.
Materials and methods: Blood tests to test circulating endothelial cells (CECs), circulating endothelial progenitor cells (CEPS), as well as soluble angiogenic factors - VEGF, bFGF and thrombospondin-1 (TSP-1) - have been collected at the baseline, after 1 and 3 months of treatment and at the progression.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Chiara Alessandra Cella

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result